BDC-4182

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

May '27

BOLTPhase 2$7M

BDC-4182 Phase 2 Est. Readout

BDC-4182• Gastric Cancer Adenocarcinoma Metastatic122

May 2027~Confirmed

00%

Competitive Landscape

1 competitor in Gastric Cancer Adenocarcinoma Metastatic

Drug Information

Target Indication

Gastric Cancer Adenocarcinoma Metastatic

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BOLT

Bolt Biotherapeutics, Inc.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts